ArticleCancer cell international2026
Probiotic-derived EPS-ZnO nanoparticles: therapeutic potential in colorectal cancer gene regulation.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC), the third most common and second deadliest cancer worldwide, arises from the abnormal growth of epithelial cells in the colon or rectum. This study focused on the oncogenes BCL9, KRAS, and WNT10A, alongside the tumor suppressor genes PDCD4, PTEN, and LRIG3, in the SW480 cell line. Probiotics, valued for their antioxidant and anti-cancer effects-especially due to their exopolysaccharides (EPS)-are promising in cancer prevention. Nanoparticles (NPs) hold great potential for diagnosing and treating various diseases, including cancer. Among them, zinc oxide NPs (ZnONPs) stand out for their unique physical and chemical properties, making them widely used in drug delivery, cancer diagnosis, and therapy. In this study, EPS were extracted and purified from the probiotic bacterium Lactiplantibacillus plantarum at a concentration of 301 ± 0.12 mg/L, and subsequently employed in the biosynthesis of ZnONPs, achieving an optimal yield of approximately 61.2%. Validation tests (UV-Vis, XRD, FTIR, FE-SEM, TEM, and zeta potential analysis) were conducted on the ZnONPs coated with exopolysaccharide (EPS-ZnONPs). The cytotoxicity of EPS and EPS-ZnONPs was assessed on the SW480 cell line, and their antioxidant properties were evaluated. Quantitative cycle variations (∆∆Cqs) measured via the Real-time PCR system, following the treatment of the cancerous cell line with the target metabolites, demonstrated reduced expression of oncogenes and increased expression of tumor suppressors. The results indicated that EPS extracted from probiotics, as well as EPS-ZnONPs, could serve as effective agents in the treatment of CRC by modulating the expression levels of genes involved in the development of this cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.